Sign In
Buy CFRX
$0.0500
+0 (+0%)
At Close: Mar 04, 2024
CFRX: Enrollment Continues in Phase 3 Trial of Exebacase…
09:50am, Wednesday, 19'th Aug 2020
By David Bautz, PhD NASDAQ:CFRX READ THE FULL CFRX RESEARCH REPORT Business Update Update on Phase 3 DISRUPT Trial In January, 2020, ContraFect announced the first patient had been dosed in the Phase
ContraFect Reports Second Quarter 2020 Financial Results and Provides Business Update
11:30am, Friday, 14'th Aug 2020
Exebacase Phase 2 study results published in the Journal of Clinical Investigation Continued patient enrollment in ongoing Phase 3 DISRUPT study of exebacaseSuccessful public equity offering, private
YONKERS, N.Y., July 20, 2020 -- ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents.
How Much Are ContraFect Corporation (NASDAQ:CFRX) Insiders Spending On Buying Shares?
12:48pm, Friday, 03'rd Jul 2020
It is not uncommon to see companies perform well in the years after insiders buy shares. The flip side of that is that...
2 “Strong Buy” Small-Cap Stocks That Could See Outsized Gains
02:56pm, Thursday, 18'th Jun 2020
As the number of new COVID-19 infections spikes, so has market volatility. An uptick in cases in the U.S. and China has spurred the latest burst of swings, with both the S&P; 500 and Dow Jones followi
Contrafect Announces Publication of Exebacase Phase 2 Study Results in the Journal of Clinical Investigation
11:30am, Wednesday, 17'th Jun 2020
ContraFect Corporation (CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modal
ContraFect Announces Appointment of Lishan Aklog, M.D. to Board of Directors
11:30am, Monday, 15'th Jun 2020
ContraFect Corporation (CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modal
ContraFect Announces Appointment of Lishan Aklog, M.D. to Board of Directors
12:00am, Monday, 15'th Jun 2020
YONKERS, N.Y., June 15, 2020 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery...
Hedge Funds Never Been Less Bullish On ContraFect Corp (CFRX)
05:46pm, Wednesday, 10'th Jun 2020
In this article you are going to find out whether hedge funds think ContraFect Corp (NASDAQ:CFRX) is a good investment right now. We like to check what the smart money thinks first before doing extens
CFRX: Four Abstracts Published in 30th ECCMID Abstract Book; Financing Overhang Removed as Pfizer Makes Second Investment…
10:43am, Friday, 29'th May 2020
By David Bautz, PhD NASDAQ:CFRX READ THE FULL CFRX RESEARCH REPORT Business Update Four Abstracts Published in 30th ECCMID Abstract Book On May 11, 2020, ContraFect Corp. (NASDAQ:CFRX) announced four
ContraFect Corporation Announces Private Placement of Common Stock and Warrants to Pfizer Inc.
11:30am, Tuesday, 26'th May 2020
ContraFect Corporation (CFRX), a clinical-stage biotechnology company focused on discovering and developing direct lytic agents for the treatment of life-threatening infectious diseases, today announc
The Daily Biotech Pulse: FDA Nod For Aquestive, Tetraphase M&A Plot Thickens, Amarin's Vascepa In COVID Fray
11:10am, Friday, 22'nd May 2020
Here's a roundup of top developments in the biotech space over the last 24 hours.Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 21) * ADC Therapeutics SA (NYSE: ADCT) (IPOed May 15) * A
ContraFect Corporation Prices Approximately $52.5 Million Public Offering of Common Stock and Warrants
02:59am, Friday, 22'nd May 2020
ContraFect Corporation (CFRX), a clinical-stage biotechnology company focused on discovering and developing direct lytic agents for the treatment of life-threatening infectious diseases, today announc
The Daily Biotech Pulse: FDA Nod For Aquestive, Tetraphase M&A Plot Thickens, Amarin's Vascepa In COVID Fray
12:00am, Friday, 22'nd May 2020
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs May 21)
ADC Therapeutics SA (NYSE:...
ContraFect Corporation Announces Proposed Public Offering of Common Stock and Warrants
08:09pm, Thursday, 21'st May 2020
ContraFect Corporation (CFRX), a clinical-stage biotechnology company focused on discovering and developing direct lytic agents for the treatment of life-threatening infectious diseases, today announc
